Ocular Therapeutix, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ocular Therapeutix, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $58 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $35 tied up three years earlier. More money tied up than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-21.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 58% of Healthcare companies in United States.
Cash Locked Ratio
$58For every $100 of sales, $58 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $35 tied up three years earlier.
More money tied up than 96% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +1% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+1% / +441%In 3 years sales changed by +1% while total assets changed by +441%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-72.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 79% of Healthcare companies in United States.
Cash Cushion Ratio
+45%Cash, after subtracting all debt, equals 45% of its market value (net cash).
Higher than 76% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Ocular Therapeutix, Inc. made a loss over the last year. Ocular Therapeutix, Inc. owes $0.23 for every $1 it owns. Ocular Therapeutix, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOcular Therapeutix, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.79The share price is 2.79 times Ocular Therapeutix, Inc.'s book value per share, higher than 53% of Healthcare companies in United States.
Market cap
$1.5 BThe total market value of all of Ocular Therapeutix, Inc.'s shares at today's price (share price × number of shares), larger than 69% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$520 MWhat Ocular Therapeutix, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.37Net worth divided by the number of shares. The share price of $6.61 is 2.8 times this, which is the P/B above.
Return on equity (ROE)
-73.0%Ocular Therapeutix, Inc. lost 73.0% of its shareholders' money over the last year, lower than 62% of Healthcare companies in United States.
Owes vs Owns
0.23×Ocular Therapeutix, Inc. owes $0.23 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Dividend yield
NoneOcular Therapeutix, Inc. does not currently pay a dividend.
Revenue growth
-18%Revenue fell 18% in the year to Dec 2025, and grew 0% a year on average over 3 years.
Profit growth
LossOcular Therapeutix, Inc. made a loss in each of the last two years.
Profit margin
-511.9%Ocular Therapeutix, Inc. lost $512 for every $100 of revenue.
Interest cover
Not coveredOcular Therapeutix, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashOcular Therapeutix, Inc. held $660 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ocular Therapeutix, Inc.: $1.5 B ÷ $520 M (30 Jun 2026) = 2.8.
What is Ocular Therapeutix, Inc.'s return on equity?
Ocular Therapeutix, Inc. lost 73.0% of its shareholders' money over the last year, lower than 62% of Healthcare companies in United States.
How much does Ocular Therapeutix, Inc. owe compared with what it owns?
Ocular Therapeutix, Inc. owes $0.23 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Does Ocular Therapeutix, Inc. pay a dividend?
No. Ocular Therapeutix, Inc. does not currently pay a dividend.
Is Ocular Therapeutix, Inc.'s revenue growing?
Revenue fell 18% in the year to Dec 2025, and grew 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.